Cytiva assists Aurisco in building a kilogram-scale Oligo FlexFactory production line to accelerate the commercialization of small nucleic acid drugs

Cytiva and Aurisco have cooperated to build Oligo FlexFactory production line project in Yangzhou. This production base has been invested hundreds of millions of yuan and can reach an annual production capacity of hundreds of kilograms of GMP-level small nucleic acid drugs once established.

Cytiva will apply entire enterprise solution to provide Aurisco with production lines and professional technologies fulfilling commercial production standard, to accelerate Aurisco with its commercial production capacity and CDMO business layout and to enhance the capability of innovative drug commercialization.

Small nucleic acid drugs (also known as oligonucleotides) are the third-generation innovative drug after antibody drugs. With its direct effect on DNA/RNA targets, small nucleic acid drugs provide higher disease-targeting druggability and advantages in high specificity and long efficiency, showing boundless potential in cuing tumors, central nervous system, infectious disease and genetic disorders. Research institution has predicted that by 2025, the global sales of small nucleic acid drugs would exceed ten billion US dollars.

In this cooperation, Cytiva will provide Aurisco with Oligo FlexFactory production lines and professional technical and service supports covering factory design, core process equipment delivery, and the lifecycle project management, standardized methods of chemical synthesis processes, personnel training, and after-sales service after project delivery.

Currently, Aurisco has carried out CRO and CDMO services of small nucleic acid drugs in the laboratory and pilot scale tests in Shanghai with products and services from Cytiva. To meet the growing market demand, Aursico plans three production lines in Yangzhou and Cytiva will take the lead in the construction of the first production line. The production capacity is expected to reach 150 to 200 kilograms per year in the future. 

About Aurisco

Established in 1998, Aurisco is a global innovative pharmaceutical company engage in research, manufacturing and marketing of complex APIs, formulations as well as Oligo’s CRO/CDMO service. Aurisco has been deeply involved in the pharmaceutical industry for more than 20 years and commits itself to continuous technological innovation. Today the company is playing a leading role in China in the field of complex synthesis, synthetic biology, photochemistry etc., and has become a long-term partner of the well-known pharmaceutical companies worldwide. Complete quality system, sufficient production capacity and globe sales network enable the company to provide high-quality products and efficient service to customers around the world.

About Cytiva

Cytiva is a pioneer in the global life sciences sector with about 10,000 employees in more than 40 countries and regions. Cytiva commits to promoting unseen technologies and accelerating extraordinary therapies. As a trusted partner, Cytiva actively cooperates with researchers, biotechnology developers and manufacturers in the fields of academic and translational medicine, focusing on the research of biopharmaceuticals, cell and gene therapies and a series of innovative technologies represented by mRNA. Develop and manufacture transformative medicines and therapies for patients around the world through improving the capability, speed, efficiency and flexibility of drug discovery and bioprocessing.